Bracco patents expiration
1. Cardiotec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6056941 | BRACCO | Kit for the preparation of technetium TC 99m teboroxime myocardial perfusion agent |
Jul, 2019
(4 years ago) | |
Drugs and Companies using TECHNETIUM TC-99M TEBOROXIME KIT ingredient
Market Authorisation Date: 19 December, 1990
Treatment: NA
Dosage: INJECTABLE;INJECTION
CARDIOTEC family patents
2. Kinevac patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6803046 | BRACCO | Sincalide formulations |
Aug, 2022
(1 year, 8 months ago) | |
KINEVAC family patents
3. Lumason patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5686060 | BRACCO | Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography |
Nov, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10232061 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(14 years from now) | |
| US10335502 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(14 years from now) | |
| US11723869 | BRACCO | Freeze-dried product and gas-filled microvesicles suspension |
May, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-728) | Mar 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions
Dosage: FOR SUSPENSION;INTRAVENOUS
LUMASON family patents
4. Prohance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474756 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US6143274 | BRACCO | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US5846519 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2015
(8 years ago) | |
Drugs and Companies using GADOTERIDOL ingredient
Market Authorisation Date: 16 November, 1992
Treatment: Contrast agent for mri
Dosage: INJECTABLE;INJECTION
PROHANCE family patents
5. Prohance Multipack patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6143274 | BRACCO | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US5474756 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US5846519 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2015
(8 years ago) | |
Drugs and Companies using GADOTERIDOL ingredient
Market Authorisation Date: 09 October, 2003
Treatment: Contrast agent for magnetic resonance imaging
Dosage: INJECTABLE;INJECTION
PROHANCE MULTIPACK family patents